Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy of daratumumab in relapsed/refractory myeloma with renal impairment
2017-003950-18Phase 2Completed
- Sponsor
- Hellenic Society of Hematology
- Start
- Nov 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of daratumumab in multiple myeloma (MM), sponsored by Hellenic Society of Hematology. Primary endpoint: Progression-free survival. Started Nov 2017; status: completed.
02
Drugs
daratumumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2017-003950-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003950-18.